According to Gilead Sciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.10831. At the end of 2023 the company had a P/S ratio of 3.72.
Year | P/S ratio | Change |
---|---|---|
2023 | 3.72 | -5.68% |
2022 | 3.95 | 18.36% |
2021 | 3.33 | 12.73% |
2020 | 2.96 | -19.28% |
2019 | 3.66 | 1.12% |
2018 | 3.62 | 1.1% |
2017 | 3.58 | 15.47% |
2016 | 3.10 | -29.58% |
2015 | 4.41 | -22.34% |
2014 | 5.68 | -44.82% |
2013 | 10.3 | 78.9% |
2012 | 5.75 | 56.83% |
2011 | 3.67 | 0.28% |
2010 | 3.66 | -34.16% |
2009 | 5.55 | -36.37% |
2008 | 8.73 | -13.63% |
2007 | 10.1 | 2.11% |
2006 | 9.89 | -16.96% |
2005 | 11.9 | 0.5% |
2004 | 11.9 | -17.21% |
2003 | 14.3 | -0.5% |
2002 | 14.4 | -46.96% |
2001 | 27.1 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.06 | 30.73% | ๐บ๐ธ USA |
Pfizer PFE | 2.75 | -11.55% | ๐บ๐ธ USA |
AbbVie ABBV | 5.25 | 69.01% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.2 | 550.11% | ๐บ๐ธ USA |
Amgen AMGN | 5.93 | 90.65% | ๐บ๐ธ USA |
Biogen BIIB | 3.42 | 9.98% | ๐บ๐ธ USA |
Illumina ILMN | 4.09 | 31.52% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | 11.2 | 260.53% | ๐บ๐ธ USA |
Merck MRK | 5.42 | 74.40% | ๐บ๐ธ USA |